Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANCN NASDAQ:CAPR OTCMKTS:ICOTF NASDAQ:XTLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$3.25+11.7%$21.77$0.51▼$10.55$24.12M0.933.15 million shs112,338 shsCAPRCapricor Therapeutics$6.20+1.1%$6.69$5.68▼$22.90$280.25M0.681.15 million shs1.11 million shsICOTFiCo Therapeutics$0.53+1.8%$0.37$0.80▼$1.82$4.84M2.034,760 shs14,590 shsXTLBXTL Biopharmaceuticals$1.25+10.6%$3.99$0.86▼$3.05$6.76M1.132.46 million shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics-5.83%-11.28%+11.92%+166.97%+87.74%CAPRCapricor Therapeutics+1.14%-0.80%+0.16%-12.18%-71.01%ICOTFiCo Therapeutics-2.18%-7.98%+4.55%+27.03%+1.13%XTLBXTL Biopharmaceuticals+2.88%-1.57%+7.30%-28.57%-10.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$3.25+11.7%$21.77$0.51▼$10.55$24.12M0.933.15 million shs112,338 shsCAPRCapricor Therapeutics$6.20+1.1%$6.69$5.68▼$22.90$280.25M0.681.15 million shs1.11 million shsICOTFiCo Therapeutics$0.53+1.8%$0.37$0.80▼$1.82$4.84M2.034,760 shs14,590 shsXTLBXTL Biopharmaceuticals$1.25+10.6%$3.99$0.86▼$3.05$6.76M1.132.46 million shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics-5.83%-11.28%+11.92%+166.97%+87.74%CAPRCapricor Therapeutics+1.14%-0.80%+0.16%-12.18%-71.01%ICOTFiCo Therapeutics-2.18%-7.98%+4.55%+27.03%+1.13%XTLBXTL Biopharmaceuticals+2.88%-1.57%+7.30%-28.57%-10.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANCNAnchiano Therapeutics 0.00N/AN/AN/ACAPRCapricor Therapeutics 2.89Moderate Buy$22.25258.87% UpsideICOTFiCo Therapeutics 0.00N/AN/AN/AXTLBXTL Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XTLB, ICOTF, ANCN, and CAPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025CAPRCapricor TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CAPRCapricor TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CAPRCapricor TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/11/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/ACAPRCapricor Therapeutics$13.39M21.17N/AN/A$3.20 per share1.94ICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/AXTLBXTL Biopharmaceuticals$450K15.14N/AN/A$1.00 per share1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANCNAnchiano Therapeutics-$27.12M-$3.4621.67N/AN/AN/A36.08%27.40%N/ACAPRCapricor Therapeutics-$40.47M-$1.64N/AN/AN/AN/A-62.71%-50.82%11/12/2025 (Estimated)ICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/AXTLBXTL Biopharmaceuticals-$1.03MN/A0.00∞N/AN/AN/AN/AN/ALatest XTLB, ICOTF, ANCN, and CAPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025CAPRCapricor Therapeutics-$0.54N/AN/AN/A$0.48 millionN/A8/11/2025Q2 2025CAPRCapricor Therapeutics-$0.48-$0.57-$0.09-$0.57$2.60 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANCNAnchiano TherapeuticsN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANCNAnchiano TherapeuticsN/A3.253.25CAPRCapricor TherapeuticsN/A4.374.37ICOTFiCo TherapeuticsN/A0.720.72XTLBXTL BiopharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANCNAnchiano Therapeutics9.05%CAPRCapricor Therapeutics21.68%ICOTFiCo TherapeuticsN/AXTLBXTL Biopharmaceuticals4.40%Insider OwnershipCompanyInsider OwnershipANCNAnchiano Therapeutics6.88%CAPRCapricor Therapeutics10.50%ICOTFiCo TherapeuticsN/AXTLBXTL Biopharmaceuticals29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableCAPRCapricor Therapeutics10145.72 million40.92 millionOptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableXTLBXTL BiopharmaceuticalsN/A5.45 million3.87 millionNot OptionableXTLB, ICOTF, ANCN, and CAPR HeadlinesRecent News About These CompaniesXTL Biopharmaceuticals Approves Key Resolutions at Shareholder MeetingJuly 28, 2025 | tipranks.comXTL Biopharmaceuticals Stock (NASDAQ:XTLB), Insider Trading ActivityJuly 8, 2025 | benzinga.comXTL Biopharmaceuticals Ltd. (XTLB) - Yahoo FinanceJune 30, 2025 | uk.finance.yahoo.comXTL Biopharmaceuticals names Noam Band as CEOApril 9, 2025 | uk.investing.comXTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive OfficerApril 8, 2025 | finanznachrichten.deXTL Biopharmaceuticals Appoints Noam Band as CEOApril 7, 2025 | tipranks.comXTL Names Mr. Noam Band as its New Chief Executive OfficerApril 7, 2025 | globenewswire.comXTL Biopharmaceuticals Reports Financial Results Amid Regional UnrestDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional ChallengesDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock, Short Interest ReportNovember 5, 2024 | benzinga.comXTL Biopharmaceuticals Ltd (XTLB)September 5, 2024 | investing.comXTL Biopharmaceuticals Ltd XTLBAugust 22, 2024 | morningstar.comMXTL Biopharmaceuticals acquires AI firm Social ProxyAugust 16, 2024 | uk.investing.comXTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionAugust 14, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. (XTLB.TA)July 22, 2024 | finance.yahoo.comXTL Entered Definitive Agreement to Acquire The Social ProxyJune 5, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. ADRApril 26, 2024 | wsj.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%March 20, 2024 | msn.comUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top ViewsMarch 20, 2024 | msn.comDow Surges 350 Points; Fed Holds Rates SteadyMarch 20, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTLB, ICOTF, ANCN, and CAPR Company DescriptionsAnchiano Therapeutics NASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Capricor Therapeutics NASDAQ:CAPR$6.20 +0.07 (+1.14%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$6.17 -0.03 (-0.55%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. iCo Therapeutics OTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.XTL Biopharmaceuticals NASDAQ:XTLBXTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
